. Author manuscript; available in PMC: 2016 May 26.

Published in final edited form as: Clin J Oncol Nurs. 2010 Apr;14(2):149–152. doi: 10.1188/10.CJON.149-152

Table 1.

Comparison of Current Myeloma Staging Systems

STAGE	DURIE-SALMON PLUS^a	INTERNATIONAL STAGING SYSTEM^b
I	Stage Ia: one focal lesion or plasmacytoma Stage Ib: fewer than five focal lesions; mild diffuse disease	Serum beta-2 microglobulin lower than 3.5 mg/L Serum albumin 3.5 g/dl or higher
II	Stage IIa and IIb: 5–20 focal lesions; moderate diffuse disease	Neither stage I nor stage III
III	Stage IIIa and IIIb: more than 20 focal lesions; severe diffuse disease	Serum beta-2 microglobulin 5.5 mg/L or higher

From “The Role of Anatomic and Functional Staging in Myeloma: Description of Durie/Salmon PLUS Staging System,” by B.G. Durie, 2006, European Journal of Cancer, 42, p. 1540. Copyright 2006 by Elsevier Limited. Adapted with permission.

From “International Staging System for Multiple Myeloma,” by P.R. Greipp, J.S. Miguel, B.G. Durie, J.J. Crowley, B. Barlogie, J. Blade, … J. Westin, 2005, Journal of Clinical Oncology, 23, p. 3415. Copyright 2005 by the American Society of Clinical Oncology. Adapted with permission.